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Abstract Renal transplantation (RTx) is the only curative
treatment for most cases of congenital and infantile nephrotic
syndrome (NS) caused by genetic defects in glomerular
podocyte proteins. The outcome of RTx in these children is
usually excellent, with no recurrence of nephrotic syndrome. A
subgroup of patients with the Finnish type of congenital ne-
phrosis (CNF), shows, however, a clear risk for post-RTx
proteinuria. Most of these patients have a homozygous trun-
cating mutation (Fin-major mutation) in the nephrin gene
(NPHS1), leading to total absence of the major podocyte
protein, nephrin. After RTx, these patients develop anti-
nephrin antibodies resulting in nephrotic range proteinuria.
Plasma exchange combined with cyclophosphamide and anti-
CD20 antibodies has proved to be successful therapy for these
episodes. NS recurrence has also occurred in a few patients
with mutations in the podocin gene (NPHS2). No anti-podocin
antibodies have been detectable, and the pathophysiology of
the recurrence remains open. While most of these episodes
have resolved, the optimal therapy remains to be determined.
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Introduction
Congenital nephrotic syndrome (CNS), defined as severe
proteinuria during the first 3 months of life, leads to
hypoproteinemia, oliguria, edema, and other consequences
of severe protein loss such as hyperlipidemia, hypothyreosis,
and risk for thrombotic complications and infections [1]. Most
cases of CNS are autosomal recessive diseases caused by
genetic defects in different components of the glomerular
filtration barrier (primary CNS), especially by mutations in
nephrin (NPHS1, nephrotic syndrome type 1) and podocin
(NPHS2) genes. Secondary forms of CNS are rare and often
caused by treatable infections (congenital syphilis, toxoplas-
mosis, malaria, cytomegalovirus, rubella).
For most primary forms of CNS, the only curative treat-
ment is kidney transplantation (RTx). The outcome of RTx in
the vast majority of patients with primary CNS is excellent
with no signs of recurrence of the original disease. In a small
minority, however, post-RTx proteinuria develops and forms a
diagnostic and therapeutic challenge. It must be emphasized
that recurrence of proteinuria after RTx is quite common in
non-genetic forms of steroid-resistant nephrotic syndrome
(SRNS) [2], which account for the majority (80 %) of SRNS
cases in childhood. This review focuses exclusively on the
rare cases of recurrence in patients with genetic causes of
CNS.
Genetic causes of CNS
In 1956, Niilo Hallman et al. reported eight infants with
nephrotic syndrome (NS) from birth, resistant to all treatment
and leading to death within the first year of life [3]. This entity
was called CNS of the Finnish type (CNF) and it is still the
prototype for CNS. In 1998, Marjo Kestilä and co-workers [4]
isolated the gene responsible for CNF, named it NPHS1, and
the same group localized its gene product, nephrin, to the slit
diaphragm (SD) connecting the podocyte foot processes in the
glomerular capillary wall [5]. Nephrin is a transmembrane
adhesion protein of the immunoglobulin family containing
1,241 amino acids (Fig. 1). The extracellular part of nephrin
has eight immunoglobulin-like motifs and one type III
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fibronectin domain [4]. Nephrin molecules from neighboring
foot processes of separate podocyte cells are thought to inter-
act in the center of the SD through homophilic interactions,
thus forming a zipper-like structure. The nephrin molecules
also interact at the cell surface with shorter Neph molecules.
The intracellular domain has nine tyrosine residues, some of
which become phosphorylated during ligand binding.
Nephrin takes part in cell signaling and is important in
connecting the SD to actin cytoskeleton of the podocyte foot
process [6]. Mutations in NPHS1 usually lead to severe pro-
teinuria from birth, but some patients have their NS onset later
in childhood. More than 200 mutations in NPHS1 have
emerged (www.biobase-international.com), most of which
lead to a severe clinical form of CNS. The Finnish patients
have two founder mutations: Fin-major (nt121(del2)) leading
to a truncated 90 residue protein, and Fin-minor (R1109X)
leading to a truncated 1,109-residue protein. Approximately
two-thirds (63 %) of the Finnish patients have Fin-major/Fin-
major genotype, 18 % are Fin-major/Fin-minor compound
heterozygotes, and 9 % are Fin-minor/Fin-minor homozy-
gotes [7].
CNF patients must be treated symptomatically with albumin
infusions, a protein-rich diet, thyroxin and anticoagulation, and
aggressive treatment of septic infections [8]. As long as the
patients do well and grow and develop normally, one can just
monitor them. However, severely proteinuric patients, especial-
ly those with reduced growth and frequent infections, should
undergo early nephrectomy and RTx, which can be performed
with retroperitoneal placement of the graft when their weight is
over 10 kg [1].
In 2000, Boute et al. described another gene, NPHS2,
encoding for an important podocyte protein, podocin [9].
Mutations in NPHS2 lead to typical CNS but also to NS
manifesting later in life. Podocin is an intracellular linker
protein that interacts with nephrin and serves a scaffolding
function for the SD. More than 60 pathogenic mutations
Fig. 1 The model of the slit
diaphragm (SD) showing some of
the major components (top).
Nephrin is a transmembrane
protein with extracellular Ig-
domains (circles) and one
fibronectin type domain
(hexagon) (middle). Fin-major
(nt121(del2)) mutation leads to a
truncated protein of only 90
residues (out of 1,241 amino
acids). E189X mutation also
results in severely truncated
protein (189 residues). Podocin is
an intracellular protein belonging
to the stomatin family (bottom).
Both R138Q and R138X are
common mutations leading to a
severely truncated podocin
protein. Similarly, L347X, which
is caused by a single nucleotide
deletion (948delT) in the last
podocin exon, results in a
truncated protein
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described can lead to steroid-resistant nephrotic syndrome
(SRNS) presenting from birth to adulthood [10]. The R138Q
mutation is associated with early onset NS. The histological
presentation is usually one of focal segmental glomerulosclerosis
(FSGS).
NPHS1 andNPHS2mutations account for about 75% of the
primary CNS cases [11]. They both cause isolated CNS without
major extrarenal manifestations. Other important etiologies
(Table 1) are phospholipase C epsilon-1 (PLCE1, [12]) and
Wilms tumor gene 1 (WT1, [13]), mutations that typically cause
diffuse mesangial sclerosis (DMS) and progressive impairment
of renal function. Laminin β2 (LAMB2) mutations also cause
microcoria and the so-called Pierson’s syndrome [14].
Decaprenyl-diphosphate synthetase subunit 2 (PDSS2) and co-
enzyme Q2 4-hydroxybenzoate polyprenyltransferase (COQ2)
mutation causemuscular symptoms of mitochondriopathies [15,
16]. Genetic defects in ARHGDIA that encodes Rho gua-
nosine diphosphate dissociation inhibitor-α have recently
been shown to cause CNS and neurological handicap [17,
18].
Renal transplantation in infants with CNS
Reports frommost registries and larger centers show that graft
and patient survival after RTx in infants is at least as good as in
older children [19]. A recent Canadian study showed that the
greatest risk for graft failure was in young adults—not in
infants [20]. One Scandinavian study showed results as good
in infants as in older patients [21]. Cultural and socioeconomic
differences do, however, exist, and results are hard to compare
[22, 23]. Today it is clear that early RTx is indicated in CNS
patients, as most long-term acquired problems develop during
the nephrotic or uremic stage. Perioperative problems in
infants are comparable to those in older children and adults.
An adult graft, however, can be placed extraperitoneally only
after the child weighs about 10 kg. Before that, an
intraperitoneal placement of the graft can be considered.
Postoperatively, excessive fluids are needed to adequately
perfuse the kidney graft [24]. Long-term graft function in
infants is similar to that in older children. A recent finding
has also shown that growth is good, in fact catch up growth in
infants is better [25], puberty is normal, and final height
is acceptable in patients transplanted as infants [26].
Neurocognitive function in children without co-morbidities
or complications before RTx is satisfactory and family coping
is excellent in developed societies with social support [27].
Proteinuria after RTx
After RTx, mild proteinuria is not rare. The most common
causes are chronic allograft injury, de novo glomerulopathy
and drug toxicity. In this context, a special problem is non-
genetic FSGS; this is a major cause of SRNS and in children
accounts for 11 % of end-stage renal disease [28]. Heavy
proteinuria recurs in 20-40 % of the patients, often within
days after RTx [29]. A circulating plasma factor has been
suggested as being responsible, and recent research has sug-
gested that circulating soluble urokinase receptor (suPAR),
increased TNF-α activity, or additional factors are involved
[30, 31].
Recurrent proteinuria in NPHS1 patients
In 1992, Laine et al. reported on 28 CNF patients, of whom six
(24 %) developed severe proteinuria and NS 1-33 months
Table 1 Some important podocyte genes, mutations of which can lead to congenital nephrotic syndrome (CNS) (11–18)
Gene Protein Locus Function Phenotype
NPHS1 Nephrin 19q13.1 Structural basis of SD, signaling CNS
NPHS2 Podocin 1q25-31 Links nephrin to lipid rafts CNS, SRNS
Signaling FSGS
TRPC6 Cation channel 11q21-22 Calcium influx signaling SRNS, FSGS
PLCE1 Phospholipase 10q23 Signaling SRNS, DMS, FSGS
Cε1
WT1 Wilms tumor 1 11p13 Differentiation FSGS, DMS
Denys-Drash-S
LAMB2 Laminin β2 3p21 podocyte to GBM DMS, Pierson S
PDSS2 CoenzymQ synthetase 6q21 CoQ10 production FSGS, Leigh S
COQ2 PHB-propenyl transferase 4q21,23 CoQ10 production Collapsing glomerulopathy
ARHGDIA RhoGDIα 17q25,3 GPD-diss. inhibitor FSGS
SD slit diaphragm, S Syndrome, SRNS steroid-resistant nephrotic syndrome, FSGS focal segmental glomerulosclerosis,DMS diffuse mesangial sclerosis
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after RTx [32]. Histology showed endothelial swelling and
mesangial cell proliferation. All patients were treated with
methylprednisolone (MP) and five with additional cyclophos-
phamide (CP). Only two patients went into remission, and
four grafts were lost. One patient showed proteinuria again in
the second graft 14 months after re-transplantation. Three
additional CNF patients reported to have proteinuria after
transplantation had responded, two to steroids and one to
steroids and cyclophosphamide [33–35]. This indicates that
a risk for proteinuria in CNF seems to exist after early RTx,
with some patients responding to therapy.
In 2000, Patrakka et al. described 45 CNF (NPHS1) pa-
tients receiving 51 kidneys [36]. In this Finnish cohort, 15
episodes of recurrent proteinuria occurred in 13 grafts (25 %).
All nine patients with recurrence were homozygous for the
Fin-major mutation, which leads to an early stop-codon and
total absence of nephrin in the native kidney. Rescue therapy
with CP was successful in seven episodes, but six kidneys
were lost. Antibodies reacting against the glomerulus were
found in eight of the nine patients, and high serum anti-
nephrin antibody levels were detected by an ELISA method
in four. Thus, it seems that circulating anti-nephrin antibodies
play a pathogenic role in NS recurrence. This resembles the
situation in Alport’s syndrome, in which an immune response
against the previously unseen collagen epitopes in kidney
grafts is responsible for the de-novo anti-glomerular basement
membrane disease [37].
In 2007, Kuusniemi et al. reported 65 Finnish CNF patients
who had received 77 kidneys [38]. The recurrence rate in Fin-
major/Fin-major patients was then 34 %, with anti-nephrin
antibodies found in 8/11 patients (73 %). No anti-nephrin
antibodies were detectable before RTx in the 22 patients
studied. In patients with a re-transplantation, recurrence oc-
curred in 1–22 days. One patient, after graft removal, showed
a clear increase in anti-nephrin antibodies, suggesting that the
antibodies might not always be evident in the circulation but
can still be present locally. Plasma exchange (PE) was tried in
addition to MP and CP in seven patients with nine episodes of
NS after transplantation. Only one graft was lost (11 %) in
contrast to five (45 %) in the 11 patients treated only with
steroids and CP. PE was performed on the five subsequent
days and then three times a week depending on response
thereafter. CP was given for 12 weeks and then switched to
azathioprine or mycophenolate as part of triple immunosup-
pression. Glomerular filtration rate (GFR) remained as
good as in patients without NS recurrence. One patient
failing to react to PE also received an anti-CD20 mono-
clonal antibody (Rituximab) and high-dose immunoglob-
ulin without any response. It thus seems that the recur-
rence rate is about 30 % in Fin-major/Fin-major patients, that
70 % have measurable anti-nephrin antibodies, and that most
patients react toMP and CP combined with PE, and their GFR
remains good.
In 2006, Srivastava et al. described a patient withNS 7 days
after an RTx from his aunt [39]. He had 3248G>T and
3250delG mutations in exon 24 and a 3478C>T mutation in
exon 27 and showed no nephrin expression in the kidney. No
anti-nephrin antibodies were present, but as serum permeabil-
ity activity was high it suggested a circulating factor might
play a role in re-nephrosis. In 2012, a Stanford group reported
a child with a homozygous mutation in NPHS1 with
transversion G>T at nucleotide position 565 that causes an
amino acid change in the nephrin protein: glutamic acid for
Amber (stop codon). The child underwent RTx at 2.5 years
and developed NS with anti-nephrin antibodies 6 months after
transplantation [40]. On biopsy, slight rejection appeared, and
CD20-staining was positive. The child was treated with in-
creased steroids and CP, and as no immediate reaction was
evident, Rituximab was added. The patient went slowly into
remission, and the authors speculate that Rituximab might
have contributed to that favorable result.
Table 2 shows our last six NPHS1 patients with recurrent
NS. They all received high-dose MP (15–20 mg/kg) and most
also CP and PE. Rituximab (eliminating CD20-positive B
lymphocytes) was added in five children and two patients also
received bortezomib (eliminating antibody-producing plasma
cells). All except one went into remission, now lasting for 3.5
to 7.7 years. The only patient not responding developed NS
during a H1N1 infection. In patients 2, 3, and 6 (Table 2)
Rituximab (375 mg/m2 × 2–4 weekly doses) had an immedi-
ate effect: inducing permanent remission. The pathogenic role
of antibodies is supported by the fact that three children each
had two episodes of NS which occurred soon (5–31 days)
after re-transplantation, suggesting preformed antibodies.
All Finnish patients with recurrence had severe proteinuria
and were Fin-major homozygotes, which is a rare mutation
outside Finland. The mutation stops gene reading very early,
and thus no tolerance to nephrin develops in these patients
during maturation of their immunological system. Nephrin
located in the kidney graft is therefore a completely new
antigen for Fin-major/Fin-major patients and raises an immu-
nological response. Although in non-Finnish patients a wide
variety of missensemutations, insertions and deletions appear,
development of a natural tolerance to the nephrin molecule
seems to be the rule.
In the management of these patients, our current practice is,
as soon as proteinuria is detected, to give three MP-pulses and
to start daily PE sessions. Analysis of anti-nephrin antibodies
is not routinely performed as the test may give false-negative
results. In cases with heavy proteinuria and no previous CP
therapies, commencement of oral CP medication (2.5 mg/kg/
day) is routine. If no response occurs in 3 weeks, 2–4 doses of
Rituximab (375 mg/m2) are given, and CP is switched to
mycophenolate. In cases with a previous CP exposure,
Rituximab is the first option. Our experience with bortezomib
is thus far very limited, and we have not tried anti-complement
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factor five antibodies (eculizumab). The fact that no comple-
ment deposits are present in the kidney graft with recurrence
speaks against the use of eculizumab.
Recurrent proteinuria in NPHS2 patients
An NPHS2 mutation is responsible for FSGS in 18–40 % of
affected children; in such children, most studies do not report
recurrence after renal transplantation. Post-transplant recur-
rence of proteinuria in patients affected by homozygous or
compound heterozygous NPHS2 mutations is encountered
rarely (1–2 %), compared to the 30 % recurrence rate seen
in nonhereditary FSGS [29]. However, descriptions exist of
five such patients (Table 3).
Bertelli et al. [29] reported two children homozygous for
the R138Q mutation who presented with recurrence of pro-
teinuria 10 and 300 days after RTx. Proteinuria was heavy and
occurred when the patients had normal renal function. They
were treated with plasma exchange (6–15 cycles) and cyclo-
phosphamide (2 mg/kg for 60 days and four iv pulses). Early
and late outcome in both patients was good [29].
Billing et al. reported a patient with a single-nucleotide dele-
tion in exon 8 of NPHS2 (948delT), for which the patient was
homozygous [41]. At the age of 4.5 years, this patient received a
renal graft from her mother. On day 7 after RTx, she developed
progressive proteinuria (urine protein/creatinine ratio 2.4 g/g),
which responded in one week to prednisone pulse therapy and
increased CsA dosage. The patient has maintained stable graft
function and no recurrence of proteinuria has been observed.
Becker-Cohen et al. described a 9-year-old girl with SRNS
presenting at the age of 2 months [42]. She was homozygous
for the R138X mutation, which causes truncation of the
podocin protein and is the most common cause of familial
SRNS among Arab children. Four years after RTx from a
deceased donor, significant proteinuria appeared and gradual-
ly increased into the nephrotic range. In biopsy, no signs of
acute rejection emerged, and a search for anti-podocin anti-
bodies could exclude their presence. Plasma exchange was
started three times weekly for 9 months then twice weekly for
2 weeks. No immediate response was documented, immuno-
suppression was kept unchanged, with no antiproteinuric
medication given. However, subsequently proteinuria de-
creased significantly.
Table 2 Treatment and outcome of the last six Finnish CNS patients with recurrence of proteinuria and nephrotic syndrome after RTx
Patient Mutation dgn RTx, age Re-nephrosis
(no)
Time after
RTx (mo)
Therapy Outcome
(+ time since last
remission in bold)
1
UTI, polyoma,
rejections
Fin-major homozygote at birth 1y 7mo 1) 51 MP, Cyclo, PE Remission
7y 7mo
2 Fin-major homozygote at birth 2y 4mo 1)
2)
3)
4)
5)
6)
4, 5
12
23
26
31
40
MP, Cyclo, PE
MP, Cyclo, PE
MP, Cyclo, PE
MP, Cyclo, PE, ACE
MP, Cyclo, PE, ACE
MP, Rituxi x4, ACE
Remission
“
“
“
“
Remission
6y
3 Fin-major homozygote at birth 1y 1mo 1)
2)
40
42
MP, Cyclo, PE
ACE
MP, Rituxi x4
ACE
Remission after 1mo
Remission
5y 6mo
4 Fin-major homozygote at birth 2y 10mo 1)
2)
4
5
20
MP, PE, Rituxi x4
Cyclo
MP, PE, Bortetsomibi x4
Rituxi x1
Remission after 12mo
still γ-glob. infusions
Remission 3y 7mo
5
H1N1
Fin-major homozygote at birth 1y 4mo 1)
2)
32
60
MP, Cyclo, PE
+Rituxi x2
+ACE
+Bortetsomibi x4
+Rituxi x1
MP, Rituxi x4
ACE
U-prot:
1.5 g/l
Transplant
nephropathy, HD
6 Fin-major homozygote at birth 1y 8mo 1) 13
14
MP, Cyclo, PE
Rituxi x2
Remission after 11mo
Remission 4y 6mo
RTx renal transplantation, y year, mo month, MP methylprednisolone, Cyclo cyclophosphamide, PE plasma exchange, ACE angiotensin-converting
enzyme inhibition, Rituxi Rituximab, CNS congenital nephrotic syndrome, UTI urinary tract infection
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Weber et al. described one patient from a cohort of 32
patients with homozygous or compound heterozygous muta-
tions inNPHS2 [43]. The patient was homozygous for R138X
mutation and developed biopsy-proven FSGS 2 years after a
third RTx, this one from her mother. No anti-podocin antibod-
ies appeared in indirect immunofluorescence.
Höcker et al. reported a pediatric RTx patient with a het-
erozygous R138Q mutation and a heterozygous splice-site
mutation (IVS 4-1,G-T) before exon 5, together leading to
NPHS2-associated FSGS [44]. She developed biopsy-proven
recurrence of FSGS 10 years post-RTx in association with
conversion from CsA-based to sirolimus-based immunosup-
pression. A re-switch of the immunosuppressive regimen back
to CsA led to a noticeable decrease in proteinuria and to
stabilization of graft function.
SRNS caused by NPHS2 mutations is regarded as an
autosomal recessive disorder requiring mutations in both
alleles. In some patients, however, only a solitary hetero-
zygous mutation has been detectable and a few of these
patients have demonstrated post-RTx recurrence of protein-
uria [29]. It has been postulated that patients with a single
mutation have a different underlying pathogenesis of their
disease, which could involve defects in other proteins
composing the glomerular barrier or a combination of
decreased podocin expression together with immunological
injury.
In contrast to the situation in NPHS1, the pathomechanism
of the recurrent proteinuria in NPHS2 patients remains un-
known and probably is multifactorial. As pointed out earlier,
no anti-podocin antibodies have been detectable in any of the
patients studied. The most common mutations in NPHS2
patients with recurrence have been R138X, which leads to a
truncated podocin protein, and R138Q, resulting in a change
of a highly conserved arginine to glutamine. Theoretically,
immunologic response in a NPHS2 patient with two
truncatingmutations is reasonable, as the kidney graft presents
to the recipient “new” podocin epitopes. On the other hand,
immunization seems less likely in a patient with only an
amino acid change in the native podocin. Moreover, the
fact that podocin is an intracellular podocyte protein
makes it a less attractive target for immunological attack
as compared to nephrin, which forms the backbone of the
extracellular SD.
Post-RTx recurrence of proteinuria in non-genetic FSGS
is believed to be caused by a circulating “proteinuric fac-
tor”, which has thus far not been isolated [2]. This factor
increases permeability of the glomerular filtration barrier.
Interestingly, Carraro et al. reported increased permeability
activity in sera from five patients with NPHS2 mutations
[45]. In one patient with post RTx recurrence, the serum
activity clearly correlated with proteinuria, and after com-
mencement of plasma exchange, this activity disappeared in
parallel with normalization of proteinuria. Overall, these
experiments support an interaction between genetics and circu-
lating factors in generating NS. Although the molecular basis of
this remains unknown, therapy with PE and CP seems reason-
able also in FSGS patients with podocin mutations and recur-
rence of NS after RTx.
Living-related RTx from donors bearing heterozygous
NPHS2mutations seem not to be associated with an increased
risk of proteinuria after RTx [46]. The few patients with
recurrence have undergone either cadaveric or living-related
RTx. The recommendation is, however, that genetic analysis
of the potential donor be performed. Adult-onset SRNS
has been described in patients heterozygous for a path-
ogenic NPHS2 mutation together with a pR229Q vari-
ant. As this variant appears in 3.6 % of the population,
the risk exists that a parent of a patient with an NPHS2
mutation might also bear the pR229Q variant, which might
later lead to proteinuria.
Table 3 Treatment and outcome of CNS patients with NPHS2 and recurrence of proteinuria and nephrotic syndrome after RTx (29, 41–45)
Patient
no
Nucleotide
change
Exon Coding
sequence
Age at
RTx
Proteinuria
after RTx
Proteinuria Treatment Outcome
1 413G>A
413G>A
3 R138Q
R138Q
9 y 10 d 2–3 g/l PE
Cyclo
Good
2 413G>A
413G>A
3 R138Q
R138Q
4.5 y 300 d 2–3 g/l PE
Cyclo
Good
3 412C>T
412C>T
3 R138X
R138X
3.1 y 4 y TP/Cr
5.5 g/g
PE Stable
4 948delT
948delT
8 L347X
L347X
4.5 y 7 d 2.4 g/l MP -pulses Good
5 412C>T
412C>T
3 R138X
R138X
2 y
6 413G>A
IVS4-1,G>T
3
5
R138Q
Split
7 y 10 y 10.7 g/m2 Switch from
sirolimus to CsA
Good
RTx renal transplantation, y year, d day, PE plasma exchange, Cyclo cyclophosphamide,MPmethylprednisolone, CsA cyclosporine A, TP total protein,
Cr creatinine, CNS congenital nephrotic syndrome
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Key summary points
- Severe proteinuria and NS are very rare in primary CNS
patients after RTx
- The most probable etiology is NPHS1 with a gene muta-
tion leading to absence of nephrin, as occurs in Fin-major
homozygotes
- In the majority of these patients, anti-nephrin antibodies
are detectable after RTx
- Sometimes NS can develop after RTx in patients with
NPHS2 mutations, but the mechanisms are still elusive
- The best treatment options known today are MP, cyclo-
phosphamide, and plasma exchange alone or combined with
Rituximab
Conclusions
Recurrence of nephrosis in CNS after renal transplantation is
extremely rare except in Finmajor/Fin-major mutations, where
it appears in 30 % of patients. It has been documented in
NPHS2 but not in other podocyte gene mutations. In NPHS1,
anti-nephrin antibodies seem to play a role, and in NPHS2,
circulating factors may be involved. In both MP, CP and PE
seem to work and in NPHS1 with several episodes of re-
nephrosis, Rituximab seems to lead to permanent remission.
Some patients who have their re-nephrosis triggered by a
severe infection or rejection may be more therapy resistant.
Multiple-choice questions (answers are provided following
the reference list)
1. The outcome of renal transplantation in infants with a
genetic form of nephrotic syndrome is usually:
a. worse than in older children
b. comparable to that in older children
c. better than in older children
2. The risk for recurrence of nephrotic syndrome after trans-
plantation in patients with a genetic kidney disease is:
a. very high
b. moderate
c. very low
3. Recurrence of nephrotic syndrome after renal transplan-
tation is most common in patients with mutations in the:
a. nephrin gene (NPHS1)
b. podocin gene (NPHS2)
c. phospholipase c-epsilon gene (NPHS3)
4. Because of recurrence risk, a child with nephrin gene
mutations should receive the graft from:
a. one of the parents
b. an unrelated, deceased donor
c. either a living-related or deceased donor
5. Patients with a post-transplant recurrence of nephrotic
syndrome have been successfully treated with a combi-
nation of:
a. increased prednisone and anti-thymocyte globulin
b. plasma exchange and cyclophosphamide
c. increased cyclosporine and mycophenolate
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